Expression of CCL17 and CCL22 by latent membrane protein 1‐positive tumor cells in age‐related Epstein–Barr virus‐associated B‐cell lymphoproliferative disorder
Open Access
- 6 February 2008
- journal article
- Published by Wiley in Cancer Science
- Vol. 99 (2) , 296-302
Abstract
Age‐related Epstein–Barr virus‐positive (EBV+) B‐cell lymphoproliferative disorder (ALPD) is a disease entity identified from a large‐scale re‐survey of cases diagnosed as diffuse large B‐cell lymphoma. ALPD is a group of EBV+ polymorphic B‐cell lymphoma typically seen in elderly patients. An age‐associated decline in host immunity against EBV might be partly responsible for the pathogenesis of ALPD. Histologically, ALPD is often characterized by a minor proportion of EBV‐encoded RNA‐positive tumor cells in a background of extensive cellular infiltration, similar to that of classical Hodgkin's lymphoma. In contrast to Hodgkin and Reed–Sternberg cells, ALPD tumor cells are clearly positive for B cell markers CD20 and/or CD79a. Hodgkin and Reed–Sternberg cells produce various chemokines, including CCL17 and CCL22, that attract chemokine receptor CCR4‐expressing Th2 cells and regulatory T cells. Previously, we have shown that EBV‐immortalized B cells also produce CCL17 and CCL22 through latent membrane protein 1 (LMP1)‐mediated activation of nuclear factor κB. Here we examined expression of CCL17 and CCL22 in ALPD. ALPD tumor cells were often heterogeneous in size in accordance with the differential expression of EBV latent genes at the single cell level. LMP1‐expressing tumor cells were typically large in size and selectively positive for CCL17 and CCL22. CCR4+ cells and forkhead box protein 3+ regulatory T cells were abundantly present, and the majority of forkhead box protein 3+ cells were CCR4+. Collectively, our data show production of CCL17 and CCL22 by LMP1+ large‐sized tumor cells and accumulation of CCR4‐expressing cells including regulatory T cells in ALPD. (Cancer Sci 2008; 99: 296–302)Keywords
This publication has 34 references indexed in Scilit:
- Expression of CCL28 by Reed-Sternberg Cells Defines a Major Subtype of Classical Hodgkin's Disease with Frequent Infiltration of Eosinophils and/or Plasma CellsThe American Journal of Pathology, 2004
- Epstein-Barr Virus and CancerClinical Cancer Research, 2004
- The Scotland and Newcastle epidemiological study of Hodgkin’s disease: impact of histopathological review and EBV status on incidence estimatesJournal of Clinical Pathology, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomasInternational Journal of Cancer, 2002
- Macrophage-Derived Chemokine Expression in Classical Hodgkin's Lymphoma: Application of Tissue MicroarraysLaboratory Investigation, 2001
- THE ORIGIN OF HODGKIN AND REED/STERNBERG CELLS IN HODGKIN'S DISEASEAnnual Review of Immunology, 1998
- Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.Journal of Clinical Investigation, 1997
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996
- A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens.Journal of Histochemistry & Cytochemistry, 1995